XBiotech (STU:4XB) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4XB XBiotech Inc STU:4XB
38 GF Score
Price €2.00
GF Value €0.15
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is XBiotech Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

XBiotech's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:4XB vs ACRV, EXOZ, BYSI: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, XBiotech's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XBiotech Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XBiotech's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where XBiotech's Margin of Safety % (DCF Earnings Based) falls into.


STU:4XB
38GF Score
XBiotech Inc STU:4XB
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is XBiotech (STU:4XB) Overvalued in 2026?

Based on GuruFocus' analysis, XBiotech stock appears to be overvalued. The current stock price of €2.00 is trading 1233.3% above its estimated GF Value™ of €0.15. GuruFocus considers XBiotech to be Significantly Overvalued.

Key valuation signals for STU:4XB:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €0.15 vs. price of €2.00 (1233.3% above fair value)
  • GF Score™: 38/100 with 2 warning signs

No single metric tells the full story. See the STU:4XB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

XBiotech Business Description

Other Exchanges XBIT:USA
Address 5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
38GF Score

Get the complete analysis for STU:4XB

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.00
Price
€0.15
GF Value